Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0NS7A
|
|||
| Former ID |
DIB015089
|
|||
| Drug Name |
APN-301
|
|||
| Synonyms |
EMD-273063; Ch14.18-IL-2; Hu14.18-IL-2
Click to Show/Hide
|
|||
| Indication | Melanoma [ICD-11: 2C30; ICD-9: 172] | Phase 2 | [1] | |
| Neuroblastoma [ICD-11: 2D11.2] | Phase 2 | [2] | ||
| Company |
Apeiron biologics
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00590824) Pilot hu14.18-IL2 in Resectable Recurrent Stage III or Stage IV Melanoma. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | Clinical pipeline report, company report or official report of APEIRON Biologics. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.